Research programme: anti-cancer therapeutics - Oncodesign Precision Medicine/Servier
Alternative Names: Research programme: STarT Pancreas - Oncodesign Precision Medicine/ServierLatest Information Update: 19 Feb 2024
At a glance
- Originator Oncodesign Precision Medicine; Servier
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Pancreatic cancer